Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-20
2000-11-21
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
51425309, 51425401, 544360, 544364, 544372, A61K 31496, C07D40106, C07D40114, C07D40306
Patent
active
061503673
ABSTRACT:
A chemical compound and composition of Formula 1: ##STR1## wherein Ar represents a phenyl ring substituted by the groups like halo, alkoxy, alkyl or heteroaryl, n=1 or n=2; said compounds and compositions as being useful therapeutic agents for hypertension, ischemic, cardiovascular and other adrenergic receptor related disorders.
REFERENCES:
patent: 4668687 (1987-05-01), Yevich et al.
patent: 5180726 (1993-01-01), Carlier et al.
patent: 5599815 (1997-02-01), Fukuda et al.
Medline Abstract for Cooke et al, Vascular Medicine 2 (1), pp. 1-7 (1997), 1998.
Rachman et al, Diabetic Medicine, 12 (6) pp. 467-478, 1995.
Drug Evaluations by the American Medical Association, pp. 575-579, 1993.
Anand Nitya
Dubey Mangal Prasad
Jain Sanjay
Patnaik, deceased Gyanendra K.
Ray Madhur
Bernhardt Emily
Council of Scientific & Industrial Research
LandOfFree
1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257439